Browse Results

  • Division: : Cancer Center
  • Therapeutic Area: Leukemia, Lymphoma, and Myeloma


There are 23 clinical trial(s) matching your criteria.

Back

A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

Investigator: James Hoffman

Institutional Protocol #: 20140170

National Clinical Trials Identifier: NCT01994889

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 9/19/2014

Transplant Registry Reporting

Investigator: Martin Andreansky

Institutional Protocol #: 20057012

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 8/20/2012

Back